Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MP Materials (MP) vs Novartis AG (NVS) Price & Performance

MP MaterialsTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

MP Materials vs Novartis AG — how do they compare? MP Materials trades at $54.53 (market cap $9.86B), while Novartis AG trades at $138.17 (market cap $262.64B). The key difference: Novartis AG is far larger — about 26.6× MP Materials's market cap, and Novartis AG pays a 3.44% dividend while MP Materials pays none. Which is the better fit depends on your goals.

MPNVS
Market Cap
$9.86B$262.64B
Sector
IndustrialsHealth
52-Week High
$98.65$168.62
52-Week Low
$38.10$121.80
Enterprise Value
$9.34B$303.97B
Dividend Yield
3.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MP Materials

No Aura AI signal available yet.

Novartis AG

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MP Materials

MP Materials mines, refines, and manufactures rare earth materials and magnets in the United States. Its products are used in transportation, energy, robotics, defense, and aerospace applications.

Read more on MP

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS